FY2025 EPS Estimates for Korro Bio Reduced by Analyst

Korro Bio, Inc. (NASDAQ:KRRO) – Research analysts at Chardan Capital decreased their FY2025 EPS estimates for shares of Korro Bio in a research note issued on Wednesday, August 13th. Chardan Capital analyst K. Nakae now expects that the company will post earnings per share of ($10.05) for the year, down from their previous forecast of ($10.00). Chardan Capital currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. Chardan Capital also issued estimates for Korro Bio’s FY2026 earnings at ($7.66) EPS.

Several other brokerages also recently commented on KRRO. Raymond James Financial reduced their price objective on shares of Korro Bio from $153.00 to $147.00 and set a “strong-buy” rating for the company in a research report on Wednesday, August 13th. Cantor Fitzgerald raised shares of Korro Bio to a “strong-buy” rating in a research report on Tuesday, April 29th. HC Wainwright cut their target price on Korro Bio from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. Finally, Oppenheimer cut their target price on Korro Bio from $155.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Korro Bio presently has a consensus rating of “Buy” and an average target price of $86.83.

Korro Bio Stock Up 1.9%

Shares of KRRO stock opened at $20.26 on Monday. The company has a market cap of $190.24 million, a price-to-earnings ratio of -2.08 and a beta of 2.51. Korro Bio has a 52 week low of $10.29 and a 52 week high of $98.00. The firm has a 50 day moving average of $14.32 and a 200-day moving average of $17.90.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($2.74) EPS for the quarter, missing the consensus estimate of ($2.54) by ($0.20). The firm had revenue of $1.46 million for the quarter, compared to the consensus estimate of $0.41 million.

Hedge Funds Weigh In On Korro Bio

A number of large investors have recently modified their holdings of the company. Wells Fargo & Company MN lifted its stake in Korro Bio by 32.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,392 shares of the company’s stock valued at $129,000 after acquiring an additional 831 shares in the last quarter. Bank of Montreal Can bought a new position in Korro Bio during the 4th quarter valued at $217,000. Legal & General Group Plc lifted its stake in Korro Bio by 664.1% during the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company’s stock valued at $165,000 after acquiring an additional 3,759 shares in the last quarter. Raymond James Financial Inc. bought a new position in Korro Bio during the 4th quarter valued at $394,000. Finally, Barclays PLC bought a new position in Korro Bio during the 4th quarter valued at $395,000. 13.18% of the stock is currently owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).